Weight-loss drug effect on early breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests whether a weight-loss medication can affect breast cancer tumors before surgery. It is for postmenopausal women with early-stage, hormone-positive breast cancer who are overweight or obese.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are postmenopausal
- You have early-stage breast cancer that is hormone receptor-positive and HER2-negative
- Your tumor is at least 1 cm
- You are overweight (BMI 27 or higher) with a weight-related condition, or have a BMI of 30 or higher
- You do not have diabetes
- You have not used weight-loss medications in the past 2 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if tirzepatide (a weight loss drug) can help women and men with early-stage hormone receptor-positive breast cancer who are overweight or obese. The goal is to see if losing weight can improve outcomes after completing their initial breast cancer treatment.
This trial tests if tirzepatide, a weight-loss medication, can help postmenopausal women with hormone-positive breast cancer who have obesity. It aims to improve health outcomes after completing cancer treatment.
This study tests whether the weight-loss drug tirzepatide (Mounjaro) can help prevent breast cancer from coming back in people who are overweight and have a sign of leftover cancer cells in their blood (called MRD-positive). You must have already finished at least one year of hormone therapy for early-stage breast cancer.
This trial tests if the weight-loss drug tirzepatide can help people with obesity-related endometrial cancer before their hysterectomy. It may improve surgical outcomes and overall health.
This trial tests whether tirzepatide, a weekly injection that helps with weight loss and blood sugar control, can improve outcomes for women with obesity and early-stage endometrial cancer (or precancerous changes) who are scheduled for surgery. The goal is to see if taking this medication before surgery can help shrink the cancer or improve surgical results.
This study tests if adding a weight loss medication (tirzepatide or semaglutide) during chemotherapy helps people with early-stage endometrial cancer who are overweight or have diabetes. It aims to see if weight loss can improve treatment outcomes.
Hear when a new Hormone-receptor-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.